FMP
Baudax Bio, Inc.
BXRX
NASDAQ
Inactive Equity
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
0.0218 USD
0.0015 (6.88%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Geraldine A. Henwood Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.baudaxbio.comexchange
NASDAQ
Description
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
CIK
0001780097
ISIN
US07160F4046
CUSIP
07160F206
Address
490 Lapp Road
Phone
484 395 2440
Country
US
Employee
9
IPO Date
Nov 14, 2019
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
BXRX Financial Summary
CIK
0001780097
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
07160F206
ISIN
US07160F4046
Country
US
Price
0.02
Beta
1.58
Volume Avg.
424.85k
Market Cap
0
Shares
-
52-Week
0.0137-3.4699
DCF
29.92
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0
P/B
-
Website
https://www.baudaxbio.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest BXRX News
It looks like there's no news available.
